{"nctId":"NCT03896477","briefTitle":"Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants","startDateStruct":{"date":"2019-07-18","type":"ACTUAL"},"conditions":["Pneumonia, Pneumococcal"],"count":660,"armGroups":[{"label":"Pneumosil","type":"EXPERIMENTAL","interventionNames":["Biological: Pneumosil"]},{"label":"Synflorix","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Synflorix"]},{"label":"Prevenar 13","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Prevenar 13"]}],"interventions":[{"name":"Pneumosil","otherNames":["Serum Institute of India Pneumococcal conjugate vaccine (SIIPL-PCV )"]},{"name":"Prevenar 13","otherNames":[]},{"name":"Synflorix","otherNames":["Pneumococcal polysaccharide conjugate vaccine (adsorbed)"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy infants based on medical history and clinical assessment.\n* Between 6 and 8 weeks (ie 42 to 56 days) old, inclusive.\n* Subject's parent must provide voluntary written/thumb-printed informed consent and be willing to comply with study requirements and procedures.\n* Subjects must have been born full-term, have a weight-to-height Z score of ≥ -2 at the time of enrollment (WHO child growth standard), and be ≥ 3.5 kg at randomization.\n* Subject's parents must be available for the duration of trial participation\n\nExclusion Criteria:\n\n* Use of any investigational medicinal product prior to randomization.\n* Previous vaccination against or infection with S. pneumoniae.\n* History of anaphylactic shock or an allergic reaction to any prior vaccination.\n* Any fever, illness (including malaria).\n* Receipt of another study vaccine within 30 days of study start.\n* Chronic administration of an immunosuppressant or administration of immunoglobulins\n* History of blood disorder, primary immunodeficiency, or a sibling who has such a diagnosis or who died suddenly without apparent cause.\n* History of meningitis, seizures or any neurological disorder.\n* Exposure to human immunodeficiency virus (HIV) by history.","healthyVolunteers":true,"sex":"ALL","minimumAge":"42 Days","maximumAge":"56 Days","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) of Serotype-specific Immunoglobulin G (IgG) Antibodies Four Weeks Post-Booster","description":"The IgG antibody concentration to each of the 10 serotypes contained in Pneumosil was measured by enzyme-linked immunosorbent assay (ELISA) in serum samples collected 4 weeks after the booster dose (Visit 6).\n\nThe pneumococcal serotype-specific IgG ELISAs were performed using the World Health Organisation (WHO) reference assay at the WHO Pneumococcal Serology Reference Laboratory, at the Institute of Child Health, University College London, United Kingdom (UK), where the assay was validated.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.45","spread":null},{"groupId":"OG001","value":"2.90","spread":null},{"groupId":"OG002","value":"5.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":null},{"groupId":"OG001","value":"0.80","spread":null},{"groupId":"OG002","value":"2.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.56","spread":null},{"groupId":"OG001","value":"0.60","spread":null},{"groupId":"OG002","value":"10.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.46","spread":null},{"groupId":"OG001","value":"4.96","spread":null},{"groupId":"OG002","value":"15.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.66","spread":null},{"groupId":"OG001","value":"3.15","spread":null},{"groupId":"OG002","value":"6.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.46","spread":null},{"groupId":"OG001","value":"2.45","spread":null},{"groupId":"OG002","value":"3.87","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.28","spread":null},{"groupId":"OG001","value":"5.02","spread":null},{"groupId":"OG002","value":"9.17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.82","spread":null},{"groupId":"OG001","value":"2.39","spread":null},{"groupId":"OG002","value":"12.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":null},{"groupId":"OG001","value":"17.31","spread":null},{"groupId":"OG002","value":"14.99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.95","spread":null},{"groupId":"OG001","value":"2.16","spread":null},{"groupId":"OG002","value":"4.97","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Local and Systemic Adverse Events (AEs) Through Day 6 Following Any Vaccination","description":"Solicited local reactions included tenderness, erythema/redness and induration/swelling at the study vaccine injection site.\n\nSolicited systemic reactions included cutaneous rash, fever (based on axillary temperature), irritability, drowsiness, and decreased appetite.\n\nThe severity of all solicited AEs was graded from mild (Grade 1) to potentially life threatening (Grade 4), based on protocol-defined criteria that were derived from Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (Version 2.0, November 2014).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"83","spread":null},{"groupId":"OG002","value":"61","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"160","spread":null},{"groupId":"OG001","value":"167","spread":null},{"groupId":"OG002","value":"160","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"105","spread":null},{"groupId":"OG002","value":"108","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"110","spread":null},{"groupId":"OG002","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited Treatment-emergent Adverse Events (TEAEs)","description":"AEs include any intercurrent illness or injury during the study, clinically significant worsening of a preexisting condition, and any solicited AE that occurred or was ongoing 6 days after study vaccine administration. A TEAE is an event that was not present prior to administration of the study vaccine, or increased in intensity after administration of the study vaccine.\n\nUnsolicited AEs were graded using the scale below:\n\nGrade 1: Mild; asymptomatic or mild symptoms; intervention not indicated.\n\nGrade 2: Moderate; minimal, local, or noninvasive intervention indicated.\n\nGrade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling.\n\nGrade 4: Life-threatening consequences; urgent intervention indicated.\n\nGrade 5: Death related to AE.\n\nRelated AEs are AEs where the Investigator determined a reasonable causal relationship between the vaccine administered and the AE based on medical judgement.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"198","spread":null},{"groupId":"OG001","value":"197","spread":null},{"groupId":"OG002","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"196","spread":null},{"groupId":"OG001","value":"195","spread":null},{"groupId":"OG002","value":"186","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Adverse Events (SAEs)","description":"An SAE was a specific AE that:\n\n* Resulted in death.\n* Was life-threatening.\n* Required inpatient hospitalization or prolongation of an existing hospitalization.\n* Resulted in a persistent or significant disability or incapacity.\n* Resulted in a congenital anomaly or birth defect","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers (GMT) of Serotype-specific Opsonophagocytic Activity (OPA) Four Weeks Post-Booster","description":"The functional activity of the antibody response to the 10 serotypes contained in Pneumosil was determined in serum samples collected 4 weeks after the booster dose in a subset of 50 participants per group. This activity was determined using the 4-fold multiplexed opsonophagocytic assay (MOPA) developed at the University of Alabama at Birmingham, and performed at the WHO Pneumococcal Serology Reference Laboratory, at the Institute of Child Health, University College London, UK, where the assay was validated.\n\nA higher titer indicates increased antibody-mediated opsonophagocytosis.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"631.29","spread":null},{"groupId":"OG001","value":"282.35","spread":null},{"groupId":"OG002","value":"429.13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"885.98","spread":null},{"groupId":"OG001","value":"484.66","spread":null},{"groupId":"OG002","value":"703.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3651.54","spread":null},{"groupId":"OG001","value":"53.86","spread":null},{"groupId":"OG002","value":"6464.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3931.21","spread":null},{"groupId":"OG001","value":"1294.61","spread":null},{"groupId":"OG002","value":"6012.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7053.37","spread":null},{"groupId":"OG001","value":"4401.18","spread":null},{"groupId":"OG002","value":"8288.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1408.68","spread":null},{"groupId":"OG001","value":"845.47","spread":null},{"groupId":"OG002","value":"2464.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2622.36","spread":null},{"groupId":"OG001","value":"1381.52","spread":null},{"groupId":"OG002","value":"3131.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1620.76","spread":null},{"groupId":"OG001","value":"305.46","spread":null},{"groupId":"OG002","value":"3679.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1384.38","spread":null},{"groupId":"OG001","value":"2541.40","spread":null},{"groupId":"OG002","value":"2094.57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2998.53","spread":null},{"groupId":"OG001","value":"1427.66","spread":null},{"groupId":"OG002","value":"5687.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serotype-specific Serum IgG Antibody Concentrations ≥ 0.35 μg/mL Four Weeks Post-Booster","description":"The seroresponse rate was defined as the percentage of infants with serotype-specific IgG antibody concentrations of at least 0.35 μg/mL, which is the reference concentration for assessment of vaccine efficacy against invasive pneumococcal diseases (IPDs).\n\nThe IgG concentration to each of the 10 serotypes contained in Pneumosil was measured by ELISA in serum samples collected 4 weeks after the booster dose.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.5","spread":null},{"groupId":"OG001","value":"89.9","spread":null},{"groupId":"OG002","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"66.2","spread":null},{"groupId":"OG002","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.5","spread":null},{"groupId":"OG002","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.5","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.0","spread":null},{"groupId":"OG001","value":"99.5","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"97.5","spread":null},{"groupId":"OG002","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"91.5","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"98.0","spread":null},{"groupId":"OG002","value":"98.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serotype-specific Serum IgG Antibody Concentrations ≥ 1.0 μg/mL Four Weeks Post-Booster","description":"Seroresponse rate was also defined as the percentage of infants with serotype-specific IgG antibody concentrations of at least 1.0 μg/mL.\n\nThe IgG concentration to each of the 10 serotypes contained in Pneumosil was measured by ELISA in serum samples collected 4 weeks after the booster dose.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"88.3","spread":null},{"groupId":"OG002","value":"97.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null},{"groupId":"OG001","value":"37.7","spread":null},{"groupId":"OG002","value":"87.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.5","spread":null},{"groupId":"OG001","value":"37.9","spread":null},{"groupId":"OG002","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"96.5","spread":null},{"groupId":"OG002","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"95.0","spread":null},{"groupId":"OG002","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null},{"groupId":"OG001","value":"89.5","spread":null},{"groupId":"OG002","value":"95.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null},{"groupId":"OG001","value":"90.0","spread":null},{"groupId":"OG002","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"77.4","spread":null},{"groupId":"OG002","value":"99.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":null},{"groupId":"OG001","value":"96.9","spread":null},{"groupId":"OG002","value":"99.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null},{"groupId":"OG001","value":"83.0","spread":null},{"groupId":"OG002","value":"96.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serotype-specific Serum OPA Titers ≥ 8 Four Weeks Post-Booster","description":"The OPA seroresponse rate was defined as the percentage of infants with an OPA titer of at least 8.\n\nOpsonophagocytic activity was measured using the 4-fold multiplexed opsonophagocytic assay (MOPA) from serum samples taken 4 weeks after the booster vaccination.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"96.0","spread":null},{"groupId":"OG002","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"55.6","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"98.0","spread":null},{"groupId":"OG002","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"96.0","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"90.0","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"98.0","spread":null},{"groupId":"OG002","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serotype-specific Serum IgG Antibody Concentrations ≥ 0.35 μg/mL Four Weeks After Completion of Primary Vaccinations","description":"The seroresponse rate was defined as the percentage of infants with serotype-specific IgG antibody concentrations of at least 0.35 μg/mL, which is the reference concentration for assessment of vaccine efficacy against invasive pneumococcal diseases (IPDs).\n\nThe IgG concentration to each of the 10 serotypes contained in Pneumosil was measured by ELISA in serum samples collected 4 weeks after the second primary vaccination dose.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"96.2","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.8","spread":null},{"groupId":"OG001","value":"92.0","spread":null},{"groupId":"OG002","value":"96.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":null},{"groupId":"OG001","value":"12.8","spread":null},{"groupId":"OG002","value":"91.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.7","spread":null},{"groupId":"OG001","value":"71.2","spread":null},{"groupId":"OG002","value":"89.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"97.2","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"91.0","spread":null},{"groupId":"OG002","value":"98.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"95.3","spread":null},{"groupId":"OG002","value":"97.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null},{"groupId":"OG001","value":"75.2","spread":null},{"groupId":"OG002","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.5","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.8","spread":null},{"groupId":"OG001","value":"63.2","spread":null},{"groupId":"OG002","value":"89.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration of Serotype-specific IgG Antibodies Four Weeks After Completion of Primary Vaccinations","description":"The IgG antibody concentration to each of the 10 serotypes contained in Pneumosil was measured by ELISA in serum samples collected 4 weeks after the second primary vaccination dose.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.63","spread":null},{"groupId":"OG001","value":"1.36","spread":null},{"groupId":"OG002","value":"3.40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":null},{"groupId":"OG001","value":"0.87","spread":null},{"groupId":"OG002","value":"1.81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":null},{"groupId":"OG001","value":"0.14","spread":null},{"groupId":"OG002","value":"2.62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":null},{"groupId":"OG001","value":"0.91","spread":null},{"groupId":"OG002","value":"1.75","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.46","spread":null},{"groupId":"OG001","value":"1.73","spread":null},{"groupId":"OG002","value":"4.67","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.93","spread":null},{"groupId":"OG001","value":"1.31","spread":null},{"groupId":"OG002","value":"2.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.03","spread":null},{"groupId":"OG001","value":"2.58","spread":null},{"groupId":"OG002","value":"3.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.75","spread":null},{"groupId":"OG001","value":"0.65","spread":null},{"groupId":"OG002","value":"4.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.45","spread":null},{"groupId":"OG001","value":"8.86","spread":null},{"groupId":"OG002","value":"9.06","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":null},{"groupId":"OG001","value":"0.57","spread":null},{"groupId":"OG002","value":"1.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serotype-specific Serum OPA Titers ≥ 8 Four Weeks After Completion of Primary Vaccinations","description":"The OPA seroresponse rate was defined as the percentage of infants with an OPA titer of at least 8.\n\nOpsonophagocytic activity was measured using the 4-fold multiplexed opsonophagocytic assay (MOPA).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"73.5","spread":null},{"groupId":"OG002","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.0","spread":null},{"groupId":"OG001","value":"96.0","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.0","spread":null},{"groupId":"OG001","value":"10.2","spread":null},{"groupId":"OG002","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"69.4","spread":null},{"groupId":"OG002","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":null},{"groupId":"OG001","value":"97.9","spread":null},{"groupId":"OG002","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.8","spread":null},{"groupId":"OG001","value":"56.5","spread":null},{"groupId":"OG002","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"95.9","spread":null},{"groupId":"OG002","value":"98.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers of Serotype-specific Serum OPA Four Weeks After Primary Vaccinations","description":"Opsonophagocytic activity was measured using the 4-fold multiplexed opsonophagocytic assay (MOPA).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.67","spread":null},{"groupId":"OG001","value":"26.70","spread":null},{"groupId":"OG002","value":"98.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"182.18","spread":null},{"groupId":"OG001","value":"85.09","spread":null},{"groupId":"OG002","value":"291.98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"400.49","spread":null},{"groupId":"OG001","value":"5.35","spread":null},{"groupId":"OG002","value":"1524.31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"923.86","spread":null},{"groupId":"OG001","value":"166.74","spread":null},{"groupId":"OG002","value":"920.43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2069.84","spread":null},{"groupId":"OG001","value":"1096.84","spread":null},{"groupId":"OG002","value":"3069.95","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134.50","spread":null},{"groupId":"OG001","value":"58.24","spread":null},{"groupId":"OG002","value":"331.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"669.79","spread":null},{"groupId":"OG001","value":"577.98","spread":null},{"groupId":"OG002","value":"489.56","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.15","spread":null},{"groupId":"OG001","value":"22.40","spread":null},{"groupId":"OG002","value":"324.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"381.46","spread":null},{"groupId":"OG001","value":"690.36","spread":null},{"groupId":"OG002","value":"647.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"806.12","spread":null},{"groupId":"OG001","value":"180.97","spread":null},{"groupId":"OG002","value":"748.96","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serotype-specific Serum IgG Concentrations ≥ 0.35 μg/mL Prior to Booster","description":"The seroresponse rate was defined as the percentage of infants with serotype-specific IgG concentrations of at least 0.35 μg/mL, which is the reference concentration for assessment of vaccine efficacy against invasive pneumococcal diseases (IPDs).\n\nThe IgG concentration to each of the 10 serotypes contained in Pneumosil was measured by ELISA in serum samples collected immediately prior to the booster vaccination dose.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.2","spread":null},{"groupId":"OG001","value":"17.2","spread":null},{"groupId":"OG002","value":"53.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.7","spread":null},{"groupId":"OG001","value":"16.4","spread":null},{"groupId":"OG002","value":"33.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.0","spread":null},{"groupId":"OG001","value":"32.7","spread":null},{"groupId":"OG002","value":"70.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null},{"groupId":"OG001","value":"74.6","spread":null},{"groupId":"OG002","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":null},{"groupId":"OG001","value":"65.4","spread":null},{"groupId":"OG002","value":"84.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.1","spread":null},{"groupId":"OG001","value":"36.1","spread":null},{"groupId":"OG002","value":"37.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.6","spread":null},{"groupId":"OG001","value":"59.3","spread":null},{"groupId":"OG002","value":"86.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.1","spread":null},{"groupId":"OG001","value":"54.9","spread":null},{"groupId":"OG002","value":"65.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null},{"groupId":"OG001","value":"95.1","spread":null},{"groupId":"OG002","value":"80.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","spread":null},{"groupId":"OG001","value":"19.4","spread":null},{"groupId":"OG002","value":"24.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration of Serotype-specific Serum IgG Antibodies Prior to Booster","description":"The IgG antibody concentration to each of the 10 serotypes contained in Pneumosil was measured by ELISA in serum samples collected immediately prior to the booster vaccination dose.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":null},{"groupId":"OG001","value":"0.16","spread":null},{"groupId":"OG002","value":"0.37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":null},{"groupId":"OG001","value":"0.16","spread":null},{"groupId":"OG002","value":"0.24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.62","spread":null},{"groupId":"OG001","value":"0.22","spread":null},{"groupId":"OG002","value":"0.50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.97","spread":null},{"groupId":"OG001","value":"0.56","spread":null},{"groupId":"OG002","value":"0.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":null},{"groupId":"OG001","value":"0.43","spread":null},{"groupId":"OG002","value":"0.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":null},{"groupId":"OG001","value":"0.29","spread":null},{"groupId":"OG002","value":"0.28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.71","spread":null},{"groupId":"OG001","value":"0.48","spread":null},{"groupId":"OG002","value":"1.16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.49","spread":null},{"groupId":"OG001","value":"0.40","spread":null},{"groupId":"OG002","value":"0.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.83","spread":null},{"groupId":"OG001","value":"1.25","spread":null},{"groupId":"OG002","value":"0.72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.32","spread":null},{"groupId":"OG001","value":"0.16","spread":null},{"groupId":"OG002","value":"0.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serotype-specific Serum OPA Titers ≥ 8 Prior to Booster","description":"The OPA seroresponse rate was defined as the percentage of infants with an OPA titer of at least 8.\n\nOpsonophagocytic activity was measured using the 4-fold multiplexed opsonophagocytic assay (MOPA) from serum samples collected immediately prior to the booster vaccination dose.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"16.0","spread":null},{"groupId":"OG002","value":"25.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58.3","spread":null},{"groupId":"OG001","value":"49.0","spread":null},{"groupId":"OG002","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.6","spread":null},{"groupId":"OG001","value":"14.0","spread":null},{"groupId":"OG002","value":"63.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.5","spread":null},{"groupId":"OG001","value":"62.5","spread":null},{"groupId":"OG002","value":"54.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.5","spread":null},{"groupId":"OG001","value":"52.1","spread":null},{"groupId":"OG002","value":"72.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.4","spread":null},{"groupId":"OG001","value":"40.8","spread":null},{"groupId":"OG002","value":"63.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.4","spread":null},{"groupId":"OG001","value":"79.6","spread":null},{"groupId":"OG002","value":"36.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer of Serotype-specific Serum OPA Prior to Booster","description":"Opsonophagocytic activity was measured using the 4-fold multiplexed opsonophagocytic assay (MOPA) from serum samples collected immediately prior to the booster vaccination dose.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.57","spread":null},{"groupId":"OG001","value":"5.19","spread":null},{"groupId":"OG002","value":"5.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.53","spread":null},{"groupId":"OG001","value":"12.01","spread":null},{"groupId":"OG002","value":"16.03","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.59","spread":null},{"groupId":"OG001","value":"6.41","spread":null},{"groupId":"OG002","value":"40.66","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.60","spread":null},{"groupId":"OG001","value":"40.08","spread":null},{"groupId":"OG002","value":"32.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1756.80","spread":null},{"groupId":"OG001","value":"1725.63","spread":null},{"groupId":"OG002","value":"1688.30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.60","spread":null},{"groupId":"OG001","value":"27.95","spread":null},{"groupId":"OG002","value":"48.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.53","spread":null},{"groupId":"OG001","value":"17.67","spread":null},{"groupId":"OG002","value":"62.77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.43","spread":null},{"groupId":"OG001","value":"12.88","spread":null},{"groupId":"OG002","value":"28.20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.09","spread":null},{"groupId":"OG001","value":"57.66","spread":null},{"groupId":"OG002","value":"12.27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.62","spread":null},{"groupId":"OG001","value":"41.99","spread":null},{"groupId":"OG002","value":"81.42","spread":null}]}]}]},{"type":"SECONDARY","title":"Ratio of Serotype-specific Serum IgG GMC 4 Weeks Post-Booster to Serotype-specific IgG GMC 4 Weeks After Completion of Primary Vaccinations","description":"Booster response was measured by the ratio of IgG GMCs measured at the post-booster visit to those measured 4 weeks after completion of primary vaccinations.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.31","spread":null},{"groupId":"OG001","value":"2.09","spread":null},{"groupId":"OG002","value":"1.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":null},{"groupId":"OG001","value":"0.90","spread":null},{"groupId":"OG002","value":"1.15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.86","spread":null},{"groupId":"OG001","value":"4.30","spread":null},{"groupId":"OG002","value":"4.14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.71","spread":null},{"groupId":"OG001","value":"5.32","spread":null},{"groupId":"OG002","value":"8.92","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.91","spread":null},{"groupId":"OG001","value":"1.84","spread":null},{"groupId":"OG002","value":"1.36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":null},{"groupId":"OG001","value":"1.86","spread":null},{"groupId":"OG002","value":"1.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":null},{"groupId":"OG001","value":"1.93","spread":null},{"groupId":"OG002","value":"2.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.98","spread":null},{"groupId":"OG001","value":"3.69","spread":null},{"groupId":"OG002","value":"2.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.98","spread":null},{"groupId":"OG001","value":"1.96","spread":null},{"groupId":"OG002","value":"1.68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24","spread":null},{"groupId":"OG001","value":"3.67","spread":null},{"groupId":"OG002","value":"3.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Ratio of Serotype-specific Serum OPA GMT 4 Weeks Post-Booster to Serotype-specific OPA GMT 4 Weeks After Completion of Primary Vaccinations","description":"OPA booster response was measured by the ratio of OPA GMTs measured at the post-booster visit to those measured 4 weeks after completion of primary vaccinations.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.70","spread":null},{"groupId":"OG001","value":"9.35","spread":null},{"groupId":"OG002","value":"4.45","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.91","spread":null},{"groupId":"OG001","value":"5.36","spread":null},{"groupId":"OG002","value":"2.46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.36","spread":null},{"groupId":"OG001","value":"10.12","spread":null},{"groupId":"OG002","value":"3.89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.62","spread":null},{"groupId":"OG001","value":"7.70","spread":null},{"groupId":"OG002","value":"6.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.51","spread":null},{"groupId":"OG001","value":"4.03","spread":null},{"groupId":"OG002","value":"2.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.24","spread":null},{"groupId":"OG001","value":"14.90","spread":null},{"groupId":"OG002","value":"7.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.27","spread":null},{"groupId":"OG001","value":"2.25","spread":null},{"groupId":"OG002","value":"5.73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.79","spread":null},{"groupId":"OG001","value":"12.25","spread":null},{"groupId":"OG002","value":"11.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.74","spread":null},{"groupId":"OG001","value":"3.30","spread":null},{"groupId":"OG002","value":"3.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.81","spread":null},{"groupId":"OG001","value":"8.71","spread":null},{"groupId":"OG002","value":"7.41","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":220},"commonTop":["Upper respiratory tract infection","Irritability postvaccinal","Pyrexia","Vaccination site pain","Diarrhoea"]}}}